Search the Newsreel

Kaltura officer Eynav Azaria sells $8,810 in stock

Kaltura officer Eynav Azaria sold 6,257 shares of company stock for a total of $8,810 across two transactions in late July, following a pre-arranged trading plan. These sales occurred as Kaltura's stock surged nearly 11% over the past week, currently trading at $1.43. Azaria …

Kaltura stock trades steadily as recent revenue growth and losses frame Nasdaq valuation

Kaltura stock (KLTR) is currently trading with a market capitalization in the low hundreds of millions, balancing double-digit revenue growth with persistent net losses. The company reported approximately $172 million in revenue for fiscal year 2023, an increase from $160 million in 2022, while …

Kalaris Therapeutics appoints Liisa Bayko as CFO

Kalaris Therapeutics has appointed Liisa Bayko as its new Chief Financial Officer, bringing over 20 years of experience in biotech finance and capital markets. This appointment comes at a crucial time for the company, which is currently conducting a Phase 1b/2 clinical trial for …

Kalaris Therapeutics stock falls despite naming new CFO

Kalaris Therapeutics Inc. (NASDAQ: KLRS) shares dropped 6.4% on Monday despite the announcement of Liisa Bayko as the company’s new Chief Financial Officer. Bayko brings over 20 years of biotechnology finance experience to the biopharmaceutical company, which is currently enrolling patients in its Phase …

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer

Kalaris Therapeutics, Inc. announced the appointment of Liisa Bayko, MBA, as Chief Financial Officer, strengthening its leadership team with her 20+ years of biotechnology finance expertise. Bayko, previously a top-ranked biotechnology analyst at Evercore ISI, will help advance Kalaris' clinical development efforts for its …

Kalaris Therapeutics, Inc. Announces Appointment of Liisa Bayko to Chief Financial Officer, Effective July 20, 2026

Kalaris Therapeutics, Inc. has announced the appointment of Liisa Bayko, MBA, as its new Chief Financial Officer, effective July 20, 2026. Ms. Bayko brings over two decades of experience in biotechnology finance, strategy, and capital markets, having previously served as Managing Director, Biotech Equity …

Kalamazoo Resources Proposes Placement of 1,322,143 Shares to Support Growth Initiatives

Kalyani Steels Share Price Forecast: 3 Year Outlook to 2030

Alkali Metals reports net loss in Q1FY27 as revenue declines

Alkali Metals reports standalone net loss of Rs 0.64 crore in the June 2026 quarter

Alkali Metals appoints Sivarama Prasad Bhamidi as Independent Director

Kalamazoo Resources (ASX:KZR) Shares Retreat Nearly 18%: What Weighed on the Gold Explorer?

Kalaris: 29% received no anti-VEGF for six months after one injection

Kalaris Therapeutics reported positive Phase 1a clinical trial data for their TH103 treatment for neovascular age-related macular degeneration (AMD). The data, covering 17 treatment-naive and 3 treatment-experienced patients, showed structural and functional improvements, with 29% of treatment-naive patients not requiring additional anti-VEGF therapy for …

Enterprise value to revenue forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS

This article provides financial information for Kalaris Therapeutics, Inc. (NASDAQ: KLRS), specifically focusing on its enterprise value to revenue forward. It notes that the market is currently closed with no trades. The content seems to be a financial data page from TradingView, offering an …

Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Kalaris Therapeutics Inc. (KLRS) stock on NASDAQ, showing a current price of $4.61 with a decrease of 7.59%. It notes that there are currently no analyst ratings or earnings information available for the company. The page …

KLRS Slides As Traders Digest Weak Cash Burn Metrics

KLRS Stock Dips As Traders Weigh Cash Burn And Volatility

Kalaris Therapeutics (KLRS) stock experienced a -6.48% dip due to negative sentiment following a clinical trial setback. The company, a micro-cap biotech, shows strong liquidity with $97.2M in cash but faces significant cash burn and deep negative returns, making it a speculative, high-volatility trading …

KLRS Stock Pops As Kalaris Maps Out TH103 Catalysts

Kalaris Therapeutics Inc. (KLRS) surged 15.4% due to pivotal clinical trial success for its lead drug TH103, currently in trials for neovascular age-related macular degeneration. The company plans to present Phase 1a data at ASRS 2026 and expects initial Phase 1b/2 data in the …

Kalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD

Kalaris Inc. announced that additional patients in its Phase 1a clinical trial for neovascular age-related macular degeneration (nAMD) demonstrated improved vision. The company's lead drug candidate, KAL-101, is being investigated for its potential to offer a new treatment option for this severe eye condition. …

Kalaris Therapeutics Reports Positive Expanded Phase 1a Data for TH103 in Neovascular AMD

Kalaris Therapeutics announced positive expanded Phase 1a data for its TH103 treatment for neovascular age-related macular degeneration (AMD), showing improvements in vision and retinal health with extended treatment durability. The company is currently enrolling patients for a Phase 1b/2 trial, with preliminary data anticipated …

Kalaris shares additional Phase 1a data for AMD treatment TH103

Kalaris Therapeutics Inc. presented additional Phase 1a data for its AMD treatment TH103, showing promising results in extending retreatment intervals for both treatment-naive and treatment-experienced patients. The company reported a favorable pharmacokinetic profile suggesting greater intraocular retention and is currently enrolling patients for its …

Why Is Kalaris Therapeutics Stock Gaining Friday?

Kalaris Therapeutics (KLRS) stock gained nearly 18% on Friday after the company announced expanded data from its Phase 1a trial for TH103, an experimental treatment for neovascular age-related macular degeneration. The expanded results showed vision improvements, enhanced retinal anatomy, and extended durability with strong …

Kalina Power (ASX:KPO) Closes Up 6.25% — What’s Driving Interest in This Waste-Heat Recovery Play?

3 Promising Penny Stocks With Market Caps Over $20M

The article identifies three promising penny stocks with market caps over $20 million: DouYu International Holdings (DOYU), Kaltura (KLTR), and Nu Ride (NRDE). It provides a financial overview of each company, highlighting their strengths, challenges, and growth potential, while emphasizing that penny stocks can …

Kalina Power (ASX:KPO) Gives Back 6.7% Despite a 55% Annual Gain — Is the Waste Heat Rally Running Out of Steam?

Hoban shakes Hanjin KAL's management control again... Share gap with Walter Cho narrows to 0.41%p

Kalgoorlie Gold Mining (ASX: KAL) Moves Higher as Exploration Activity Continues

KALEKIM KIMYEVI - KAP Haberleri - 2026-07-09 tarihli

Kaltura: No Longer Willing To Trade Quality For Value (Downgrade) (NASDAQ:KLTR)

Gold Mining Stocks Gaining Attention As Lower Rate Hopes Lift Gold Prices

Kalina Power (ASX:KPO), Mitchell Services (ASX:MSV) and Sigma Healthcare (ASX:SIG): Why These ASX Stocks Are Gaining Attention

KLTR Q1 2026 Earnings: EPS Surprises with 400% Beat, Stock Edges Higher - Earnings Risk Report

Kalina Power And 2 Other ASX Penny Stocks To Watch

[Shareholder Activism in Korea: Case1] KCGI vs. Hanjin KAL(2018-2022)

Kalpataru Projects International shares rally 4% on securing ₹2,957 crore new orders

Kalyani Steels Independent Director ceases to be director